Yoshimasa Aso Pages 533 - 543 ( 11 )
Diabetic nephropathy, which represents a major form of chronic kidney disease (CKD), is a leading cause of end-stage renal disease worldwide, and is also a risk factor for cardiovascular disease (CVD). Patients with diabetes and CKD have poorer outcomes after myocardial infarction. The underlying pathogenic mechanism that links diabetic nephropathy to a high risk of CVD remains unclear. In addition to traditional risk factors, including hypertension, hyperglycemia, and dyslipidemia, identification of novel modifiable risk factors is important in preventing CVD in people with diabetes. Inflammation/oxidative stress are known to be associated with an increased risk for CVD in patients with diabetic nephropathy. Moreover, homocysteine, advanced glycation end products, asymmetric dimethylarginine, and anemia may play a role in the development and progression of atherosclerosis in patients with diabetic nephropathy. This review summarizes the epidemiologic evidence, molecular mechanisms responsible for the increased risk for CVD in patients with diabetic nephropathy, and therapeutic intervention for diabetic nephropathy as evidenced by large-scale clinical trials.
Cardiovascular Disease, Diabetic Nephropathy, chronic kidney disease (CKD), myocardial infarction, pathogenic mechanism, hypertension, hyperglycemia, dyslipidemia, homocysteine, microangiopathy
Department of Internal Medicine, Koshigaya Hospital, Dokkyo Medical University, 2-1-50 Minami- oshigaya, Koshigaya, Saitama 343-8555, Japan.